Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

An NHS paediatrician sent a WhatsApp message offering children and parents £1,500 to take part in Moderna’s Phase III ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs ...

(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.

Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and ...

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.

Real-time index price for TSX Composite Index (TXCX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...